“
“Background: Binge-eating disorder may represent a risk factor for the metabolic syndrome.

Objective: The objective was to assess longitudinally the BEZ235 molecular weight relation between

binge-eating disorder and components of the metabolic syndrome.

Design: At 2.5 and 5 y of follow-up, 134 individuals with binge-eating disorder and 134 individuals with no history of eating disorders, who were frequency-matched for age, sex, and baseline body mass index (BMI), were interviewed during the follow-up interval regarding new diagnoses of 3 metabolic syndrome components: hypertension, dyslipidemia, and type 2 diabetes.

Results: A comparison of individuals with and without a binge-eating disorder in analyses adjusted for age, sex, baseline BMI, and interval BMI change had hazard ratios (95% CIs) for reporting new diagnoses of metabolic syndrome components of 2.2 (1.2, 4.2; P = 0.023) for dyslipidemia, 1.5 (0.76, 2.9; P = 0.33) for hypertension, 1.6 (0.77, 3.9; P = 0.29) for type 2 diabetes, 1.7 (1.1, 2.6; P = 0.023) for any component, PF-03084014 and 2.4 (1.1, 5.7; P = 0.038) for >= 2 components.

Conclusion: Binge-eating disorder may confer a risk of components of the metabolic syndrome over and above the risk attributable to obesity alone.

This trial was registered at www.clinicaltrials.gov as NCT00777634. Am J Clin Nutr 2010;91:1568-73.”
“Menstrual migraine and other hormonally related headaches are common in women. Falling estrogen levels or estrogen withdrawal after periods of sustained higher levels can trigger migraine. It makes sense to target this trigger for management of hormonally related Selleckchem GSK1120212 headaches, particularly when nonhormonal strategies have been unsuccessful. Decision making regarding the use of hormonal contraception and menopausal hormone therapy is complex and commonly driven by other factors, but hormonal manipulation

can potentially improve the course of migraine. Providers caring for migraineurs are appropriately concerned about stroke risk. Estrogen-containing hormonal contraceptives are relatively contraindicated for women who have migraine with aura. Postmenopausal hormone therapy is acceptable for women with a history of migraine. For these women, transdermal estradiol is recommended. Estrogen replacement is important for women who undergo an early menopause, whether natural or induced. Practical strategies for hormonal manipulation in the management of migraine and other hormonally related headaches are presented.”
“Antibiotic resistance in probiotic strains is a matter of interest due to the increase in consumption of probiotic products. Many studies have evaluated the antibiotic susceptibility of lactobacilli or the presence of resistance determinants, while knowledge on selection of resistance during exposure to antibiotics is still limited.